Retatrutide vs Semaglutide: Triple Agonist vs GLP-1 Compared

Overview

Retatrutide and semaglutide take two very different approaches to incretin-based treatment. Semaglutide (sold as Ozempic for type 2 diabetes and Wegovy for obesity, both by Novo Nordisk) is a selective GLP-1 receptor agonist that targets a single receptor pathway. Retatrutide (LY3437943, Eli Lilly) is a triple agonist that targets the GIP, GLP-1 and glucagon receptors at once.

Retatrutide’s TRIUMPH-4 Phase 3 data, showing -28.7% mean weight loss at 68 weeks, have made the comparison much sharper. Semaglutide transformed obesity treatment by showing that GLP-1 receptor activation alone could produce clinically meaningful weight loss. Retatrutide’s multi-receptor approach appears to go a good deal further.

Important note: The only head-to-head trial of retatrutide against semaglutide is TRANSCEND-T2D-2, in adults with type 2 diabetes, compared with semaglutide 2 mg (the Ozempic dose, not the 2.4 mg Wegovy obesity dose). Lilly announced topline results on October 28, 2026; they have not yet been peer reviewed. Every other comparison on this page is cross-trial, which is limited by differences in study design, patient populations and methods. These comparisons are for context only and are not definitive evidence that one drug is better or worse.

Mechanism of Action

Semaglutide

Semaglutide is a modified human GLP-1 analogue with 94% structural similarity to natural GLP-1. It selectively activates the GLP-1 receptor with high potency and has no clinically meaningful activity at the GIP or glucagon receptors. Everything it does runs through GLP-1R:

• Appetite suppression via GLP-1 receptors in the hypothalamus and brainstem
• Glucose-dependent insulin secretion from pancreatic beta cells
• Glucagon suppression from alpha cells
• Slowed gastric emptying
• Possible cardiovascular benefits through direct effects on blood vessels

Semaglutide carries a C18 fatty diacid that binds albumin, giving it a half-life of about 7 days and allowing a once-weekly injection under the skin (or a daily pill, as Rybelsus).

Retatrutide

Retatrutide is a 39-amino-acid synthetic peptide (molecular weight ~4,731 Da) that activates three receptors: GIP, GLP-1 and glucagon. It has all of semaglutide’s GLP-1R effects plus more:

• GIPR effects on fat tissue function, extra insulin secretion and possible effects on appetite centers in the brain
• GCGR-driven increases in energy use and fat burning in the liver
• Acting on several receptors together produces synergistic metabolic effects

The key difference: semaglutide reduces calorie intake through appetite suppression alone, while retatrutide reduces intake (via GLP-1R and GIPR) and raises energy use (via GCGR), creating a larger energy deficit.

The Energy Balance Difference

That gives the two drugs very different profiles. Semaglutide is a potent appetite suppressant, one of the most effective ever made. But it works on only one side of energy balance: calories in. As weight comes off, the body adapts by lowering its resting metabolic rate (metabolic adaptation), which slows further loss and eventually causes a plateau.

Retatrutide’s glucagon component works directly against this adaptation by raising energy use through heat production and fat burning in the liver. Working on both sides of energy balance may explain why retatrutide causes more weight loss, and why its curve had not flattened at 48 weeks in Phase 2. The even stronger Phase 3 results confirmed that pattern.

Efficacy Comparison

Weight Loss

Cross-trial weight loss results, now including Phase 3 data:

Parameter	Semaglutide 2.4 mg	Retatrutide 12 mg (Phase 2)	Retatrutide (TRIUMPH-4, Phase 3)
Trial	STEP 1 (Phase 3)	Phase 2 obesity	TRIUMPH-4 (Phase 3)
Duration	68 weeks	48 weeks	68 weeks
Population	Obesity/overweight	Obesity/overweight	Obesity with knee OA
Mean weight loss	-14.9%	-24.2%	-28.7%
≥5% weight loss	~86%	~100%	Not in topline release
≥10% weight loss	~70%	~93%	Not in topline release
≥15% weight loss	~50%	~83%	Not in topline release
≥20% weight loss	~32%	~73%	Not in topline release
≥25% weight loss	—	—	58.6%
≥30% weight loss	—	—	39.4%

The TRIUMPH-4 Phase 3 results stand out for their size and because they beat the Phase 2 results. In drug development, Phase 3 results usually come in a little lower than Phase 2, because the study populations are larger and more varied. The -28.7% result at 68 weeks, nearly double semaglutide’s -14.9% at 68 weeks, is the largest weight reduction ever reported for a single obesity drug in a Phase 3 trial.

Weight Loss Trajectory

The two drugs’ weight loss curves differ in a meaningful way. In STEP 1, semaglutide’s weight loss began to level off around 60-68 weeks, as you would expect when a drug that only cuts intake meets metabolic adaptation. Retatrutide’s Phase 2 curve was still falling at 48 weeks with no clear plateau. The even larger Phase 3 result suggests that with refined dosing, the lack of a plateau is even more marked. Treatment beyond 48 weeks would be expected to bring further weight loss.

Glycemic Control

Parameter	Semaglutide 1.0 mg	Retatrutide 12 mg
Trial context	SUSTAIN (Phase 3, T2D)	Phase 2, T2D
Mean HbA1c reduction	~-1.5 to -1.8%	~-2.02%
Proportion reaching HbA1c <7%	~66-73%	Data maturing
Weight loss in T2D	~-4 to -6%	~-16.9%

Retatrutide shows numerically larger effects on blood sugar and weight in people with diabetes, though these cross-trial comparisons are limited by differences in baseline characteristics and trial design. The head-to-head TRANSCEND-T2D-2 trial (1,298 adults with type 2 diabetes, 80 weeks, open label) now gives a direct comparison: in Lilly’s topline results, A1C fell 2.2 points on both retatrutide 9 mg and 12 mg versus 1.8 on semaglutide 2 mg, and weight fell 19.5% (9 mg) and 20.9% (12 mg) versus 9.4%. Diarrhea, the most common adverse event, occurred in 28.3% and 32.7% versus 26.4%. The much greater weight loss in people with diabetes (-16.9% vs. -4 to -6%) stands out, because people with type 2 diabetes usually lose less weight on GLP-1 drugs than people without it.

Liver Fat

This may be where the difference in mechanism matters most. Semaglutide lowers liver fat modestly (about 40-50% relative reduction in dedicated MASLD studies), mostly through weight loss and indirect metabolic gains. Retatrutide’s glucagon component drives fat burning in the liver directly, giving much larger reductions (~82% relative reduction in Phase 2).

Parameter	Semaglutide	Retatrutide
Relative liver fat reduction	~40-50%	~82%
Primary mechanism	Indirect (weight loss, metabolic improvement)	Direct (GCGR-mediated hepatic oxidation) + indirect
Clinical relevance for MASLD	Modest benefit	Potentially transformative

For the tens of millions of people with both obesity and MASLD, retatrutide’s stronger liver fat clearance could be its most important clinical advantage.

Safety Comparison

Gastrointestinal Tolerability

Both drugs have similar GI side effects, driven by GLP-1R activation:

Adverse Event	Semaglutide 2.4 mg (Wegovy US label)	Retatrutide 12 mg (TRIUMPH-4, 68 weeks)
Nausea	44%	43.2%
Diarrhea	30%	33.1%
Vomiting	24%	20.9%
Constipation	24%	25.0%
Discontinuation due to AEs	6.8%	18.2%

In these figures, retatrutide’s GI rates are close to semaglutide 2.4 mg, with similar nausea (43.2% vs 44%) and constipation (25.0% vs 24%). Far more people stopped retatrutide 12 mg because of side effects in TRIUMPH-4 (18.2% vs 6.8%). In the later TRIUMPH-1 trial the figure was 11.3% at 12 mg. These are cross-trial comparisons with different populations and durations.

In the 48-week Phase 2 obesity trial, the 12 mg group reported nausea in 45%, diarrhea in 15%, vomiting in 19% and constipation in 16%.

Cardiovascular Safety

Semaglutide has completed dedicated cardiovascular outcomes trials (SUSTAIN-6 and SELECT) showing cardiovascular safety and, in SELECT, a 20% reduction in major adverse cardiovascular events (MACE) in people with overweight/obesity and established cardiovascular disease. That evidence is a significant clinical advantage for semaglutide.

Retatrutide has no cardiovascular outcomes data. Phase 2 improvements in risk factors (blood pressure, lipids) are encouraging, but firm evidence of cardiovascular safety or benefit needs dedicated outcomes studies. This is still a major gap.

Dysesthesia

TRIUMPH-4 Phase 3 data also found a new safety signal: dysesthesia (tingling, numbness or burning sensations), reported in 20.9% of the 12 mg group versus 0.7% on placebo. It was not prominent in Phase 2. It is thought to be linked to glucagon receptor activity and has not been seen at similar rates with semaglutide or other GLP-1-only drugs.

Heart Rate

Both raise heart rate. The Wegovy label reports mean increases in resting heart rate of 1 to 4 beats per minute compared with placebo. This increase has not been linked to cardiovascular harm in semaglutide’s extensive post-marketing surveillance. In retatrutide’s Phase 2 obesity trial, heart rate rose with dose, peaked at 24 weeks and declined at 36 and 48 weeks; the authors described the increases as similar to those seen with GLP-1 receptor agonists. The main text of that paper does not give the size of the rise.

Pancreatitis and Gallbladder Events

Both drugs carry warnings about possible pancreatitis, a class concern with incretin-based drugs. Rates are low (<1%) with semaglutide in large Phase 3 and real-world datasets. Retatrutide’s Phase 2 data showed no raised pancreatitis signal, but Phase 3 will have more statistical power to detect rare events.

Gallbladder events (gallstones, gallbladder inflammation) are a known effect of rapid weight loss from any cause. Both drugs carry this risk because both cause large weight loss. Semaglutide’s STEP trials reported gallbladder events in about 1.5-2.5% of patients. Retatrutide’s larger weight loss could in theory raise the risk, though Phase 2 data did not raise concern.

Thyroid Considerations

Semaglutide carries a boxed warning about thyroid C-cell tumors based on rodent studies, though their significance in people has not been established. Both semaglutide and retatrutide need monitoring for pancreatitis, a general concern with incretin-based drugs. No sign of higher pancreatitis risk emerged in retatrutide’s Phase 2 data.

Body Composition and Lean Mass

With drugs that cause large weight loss, body composition matters more and more: how much of the lost weight is fat and how much is lean mass. Losing muscle and bone along with fat can cause harm, especially in older adults, including weaker physical function, higher sarcopenia risk and higher fracture risk.

STEP trial data show that about 60-70% of the weight lost on semaglutide is fat and 30-40% is lean mass. That is broadly what you would expect from weight loss driven by eating less, and it has prompted advice to pair GLP-1 treatment with resistance exercise and enough protein.

Retatrutide adds a complication. Its glucagon component speeds amino acid breakdown in the liver, which could in theory increase lean mass loss. But glucagon also strongly drives fat burning, which may shift the body toward using fat rather than protein for fuel. The net effect on body composition is an empirical question for Phase 3 to answer. Early Phase 2 observations raised no alarms, but because retatrutide removes more weight in total (-28.7%), even the same lean mass fraction means more lean mass lost in absolute terms.

Both drugs should be used with enough protein (recommended ≥1.2 g/kg/day of ideal body weight) and resistance exercise to limit lean mass loss.

Dose Escalation and Practical Considerations

Semaglutide (Wegovy)

Wegovy uses a standard dose-escalation schedule: it starts at 0.25 mg weekly and rises monthly through 0.5, 1.0 and 1.7 mg to the maintenance dose of 2.4 mg. The full escalation takes about 16-20 weeks. This slow increase is essential for managing GI side effects; starting at the full dose would cause unacceptable rates of nausea and vomiting.

Semaglutide also comes as a pill (Rybelsus) for type 2 diabetes and, since December 2025, as the Wegovy pill (oral semaglutide 25 mg) for weight management, an option for people who want to avoid injections.

Retatrutide

Retatrutide trials have used dose-escalation schedules to reach the 12 mg target dose. The titration schedule refined for Phase 3 may have helped the better tolerability and efficacy seen in TRIUMPH-4. Once the drug is approved, the prescribed titration schedule will be critical in practice.

Both drugs are once-weekly injections under the skin, which most patients find acceptable. The injection devices, volumes and sites will differ, but the basic burden is similar.

Patient Population Considerations

Patients with Moderate Obesity (BMI 30-35)

At the lower end of the obesity range, semaglutide’s ~15% weight loss may be enough to meet clinical goals (fewer related conditions, better quality of life, a BMI <30). Retatrutide’s greater efficacy may be more than these patients need, and the risk-benefit decision should weigh semaglutide’s more established safety profile.

Patients with Severe Obesity (BMI ≥40)

For people with severe obesity, retatrutide’s extra weight loss (-28.7% vs. -14.9%) could turn a meaningful result into a life-changing one. A person weighing 130 kg would lose about 37 kg on retatrutide versus about 19 kg on semaglutide, a difference that can affect mobility, sleep apnea, diabetes remission and eligibility for surgery.

Patients with MASLD

Liver fat reduction is retatrutide’s most distinctive clinical advantage. Its ~82% relative reduction, against semaglutide’s ~40-50%, could mean the difference between a modest improvement and fatty liver almost fully cleared. For the estimated 25-30% of adults worldwide who have MASLD, that difference is clinically significant.

Patients with Cardiovascular Disease

Semaglutide has the clear advantage here. The SELECT trial showed a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg, a proven benefit retatrutide cannot yet match. For patients whose goals include lowering cardiovascular risk, semaglutide is still the evidence-based choice.

Status and Availability

Parameter	Semaglutide	Retatrutide
Approval status	FDA-approved (T2D, obesity, CV risk)	Investigational (Phase 3)
Brand names	Ozempic, Wegovy (injection and pill), Rybelsus	None
Available formulations	SC injection, oral tablet	SC injection (clinical trials only)
CV outcomes data	Yes (SUSTAIN-6, SELECT)	No
Phase 3 weight loss data	Yes (-14.9%, STEP 1)	Yes (-28.7%, TRIUMPH-4)
Real-world data	Extensive (millions of patients)	None
Prescribing experience	Years of clinical use	Not available
Expected availability	Now	Late 2027 to mid-2028 (filing planned no later than Q1 2027)
List price	$1,349/month (Wegovy) and over $1,000/month (Ozempic) as of February 2026; $675 planned from January 2027	Unknown

Semaglutide has a big head start in approval, clinical experience, real-world data and formulation options. The pill (Rybelsus) is an alternative for people who prefer not to inject. Retatrutide is earlier in development but has now passed the critical Phase 3 efficacy milestone. The full Phase 3 program, including safety analyses and the regulatory submission, must be finished before approval is possible.

Molecular Comparison

Feature	Semaglutide	Retatrutide
Peptide length	31 amino acids	39 amino acids
Molecular weight	~4,114 Da	~4,731 Da
Backbone	GLP-1 analogue	GIP-based, modified
Receptor targets	GLP-1R only	GIPR, GLP-1R, GCGR
Fatty acid	C18	C20
Half-life	~7 days	~6 days
Dosing frequency	Once weekly (SC)	Once weekly (SC)
Manufacturer	Novo Nordisk	Eli Lilly

The molecules reflect different design choices. Semaglutide is built on the natural GLP-1 backbone, tuned for maximum GLP-1R potency and a long duration of action. Retatrutide uses a GIP-based backbone as a platform for activity at three receptors at once. That is harder to engineer, because potency at each receptor has to be balanced without spoiling the molecule’s overall drug-like properties.

Who Benefits From Which Approach

These points are speculative, based on how the drugs work:

Semaglutide may be more appropriate when:

• You need a proven, FDA-approved option with extensive safety data today
• Lowering cardiovascular risk is a main goal (supported by the SELECT trial)
• You prefer a pill (Rybelsus)
• Moderate weight loss (10-15%) is enough to meet the clinical goal
• You want simpler, single-receptor pharmacology

Retatrutide may offer advantages when (pending regulatory approval):

• You need more weight loss (approaching or above 25%)
• Liver fat is a clinical priority (MASLD/MASH)
• Broad metabolic improvement beyond weight and glucose is the aim
• You have not lost enough weight on a single-agonist drug
• The energy-use effect may help break through a weight loss plateau

Long-Term Considerations

Weight Regain After Discontinuation

The STEP 1 extension and later studies showed that weight returns when semaglutide is stopped: about two-thirds of the weight lost comes back within a year. So semaglutide, like other obesity drugs, has to be taken long term to keep its benefit.

Whether retatrutide behaves the same way is unknown. Its glucagon component’s effects on metabolic rate and liver energy use could in theory reset the body’s metabolism in a way that partly lasts after the drug is stopped, but this is speculation. The TRIUMPH program may include data on weight maintenance after treatment ends.

Cost-Effectiveness

Semaglutide’s US list price (as of February 2026, $1,349 a month for Wegovy and more than $1,000 for Ozempic) has been a barrier to access. Novo Nordisk says it will cut both to $675 a month from January 1, 2027. Retatrutide’s price is unknown, but its greater efficacy may make it more cost-effective if the extra weight loss leads to proportionally fewer related diseases and less healthcare use. The real cost-effectiveness comparison will depend on long-term outcomes (cardiovascular events prevented, diabetes remissions, surgeries avoided), which will take years to gather.

A Shift in How Obesity Is Treated

The step from semaglutide to retatrutide is part of a wider trend in metabolic drugs. First-generation GLP-1 agonists (exenatide, liraglutide) produced 5-8% weight loss. Second-generation optimization (semaglutide) reached 15%. Multi-receptor drugs (retatrutide) are now reaching nearly 30%. Each generation has roughly doubled the efficacy of the last, and each has widened the group of patients for whom drug treatment is a credible alternative to surgery.

This trend suggests drugs may soon match surgical results without the irreversibility, anatomical changes and operative risk of bariatric procedures. Semaglutide started that shift; retatrutide may complete it.

Conclusion

Semaglutide and retatrutide come from different generations and design approaches. Semaglutide is an approved, proven drug with years of clinical experience, cardiovascular outcomes data and several formulations. Retatrutide is an investigational drug with a broader receptor mechanism and Phase 3-confirmed greater weight loss (-28.7% vs. -14.9%). The TRIUMPH-4 data have moved retatrutide out of the “promising but unconfirmed” category; its efficacy is now backed by Phase 3.

Still to be established: the full safety profile across the Phase 3 program, cardiovascular outcomes, long-term durability and real-world effectiveness. Semaglutide’s years of post-marketing experience give a level of confidence that retatrutide will take time to earn. For decisions made today, semaglutide is the proven, available option. Retatrutide may be the next big advance, but it is still 1-2 years from clinical practice, with Lilly planning to file no later than Q1 2027.

Summary of Key Data Points

Metric	Semaglutide 2.4 mg	Retatrutide (TRIUMPH-4)
Phase 3 weight loss	-14.9% (68 weeks)	-28.7% (68 weeks)
Liver fat reduction	~40-50%	~82%
HbA1c reduction (T2D)	-1.5 to -1.8%	-2.02%
CV outcomes data	Yes (SELECT: 20% MACE reduction)	No
Nausea rate (12 mg for retatrutide; Wegovy label for semaglutide)	44%	43.2%
Diarrhea rate	30%	33.1%
Vomiting rate	24%	20.9%
Half-life	~7 days	~6 days
Receptors	GLP-1 only	GIP + GLP-1 + Glucagon
Oral formulation	Yes (Rybelsus)	No
Approval status	FDA-approved	Phase 3
Earliest availability	Now	Late 2027 to mid-2028

Frequently Asked Questions

Is retatrutide more effective than semaglutide for weight loss?

Based on Phase 3 data, retatrutide produces much more weight loss than semaglutide. TRIUMPH-4 showed -28.7% mean weight loss at 68 weeks, compared with semaglutide’s -14.9% at 68 weeks in STEP 1. The nearly twofold difference comes from retatrutide’s extra receptor targets (GIP and glucagon), which add energy-use effects on top of appetite suppression. But these are cross-trial comparisons, not a head-to-head study, and differences in populations and design limit what you can conclude.

When will retatrutide be available?

Retatrutide is in Phase 3 clinical trials (the TRIUMPH program) and has not yet been submitted for FDA approval. The earliest realistic approval is late 2027 to mid-2028, with Lilly planning to file no later than Q1 2027 and assuming a standard review. The FDA ruled on October 2, 2026 that retatrutide is a drug, so the application must be a New Drug Application (NDA), which Lilly is contesting (the FDA ruling). For now, the only way to get retatrutide is by enrolling in a clinical trial.

Does retatrutide have more side effects than semaglutide?

The side effects are broadly similar and mostly GI. Phase 3 TRIUMPH-4 data showed retatrutide’s GI rates are close to semaglutide 2.4 mg as listed in the Wegovy label (nausea 43.2% vs 44%, diarrhea 33.1% vs 30%, vomiting 20.9% vs 24%). More people stopped retatrutide 12 mg because of side effects (18.2% in TRIUMPH-4, 11.3% in TRIUMPH-1) than the 6.8% in the Wegovy label. Both drugs raise the dose gradually to limit GI problems. The key safety difference is that semaglutide has years of real-world safety data and cardiovascular outcomes evidence, while retatrutide’s long-term safety is still being worked out.

Can you switch from semaglutide to retatrutide?

Not yet. Retatrutide is not approved and is only available in clinical trials. If it is approved, switching would be a decision for you and your doctor. The two drugs act on different receptors (retatrutide adds GIP and glucagon activity to the GLP-1 pathway semaglutide targets), so a switch would probably involve gradual dose titration. There are no clinical data on switching between them yet.

Is retatrutide better than semaglutide for fatty liver disease?

The data point to a clear advantage for retatrutide. It cut liver fat by about 82% in relative terms in Phase 2, compared with roughly 40-50% for semaglutide in dedicated MASLD studies. The difference comes from retatrutide’s glucagon component, which directly stimulates fat burning in liver cells, something semaglutide cannot do. For people with MASLD, this could be one of the most clinically important differences between the two drugs.

Will semaglutide become obsolete when retatrutide is approved?

Unlikely. Semaglutide has several strengths that will keep it relevant: a pill form (Rybelsus), proven cardiovascular benefit (SELECT trial), years of real-world safety data, more approved uses, and probably lower cost once biosimilars and generics arrive. Retatrutide may become the preferred choice for people who need maximum weight loss or have significant liver disease, but semaglutide will likely stay a first-line option for many. The two drugs may end up serving different groups of patients rather than competing head-on.